EverSea Medicines to acquire Hasten Biopharmaceuticals
Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a …
Post
-
-
FDA seeks permanent future for rare pediatric priority review vouchers
The US Food and Drug Administration (FDA) is seeking to permanently authorise the rare pediatric disease priority review voucher (PRV) …
-
Shionogi secures $482m BARDA contract to tackle AMR crisis
Japanese pharma company Shionogi has secured a contract worth up to $482m with the US’s Biomedical Advanced Research and Development …
-
Jeito Capital secures over $1.2bn for new biopharma investments
Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn), …
-
Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic
Sidewinder Therapeutics has secured $137m in a Series B financing round to progress its pipeline of bispecific antibody-drug conjugates (ADCs) …
-
RoosterBio and MineBio team up to expand MSC solutions access in China
RoosterBio has entered an exclusive distributor partnership with MineBio Life Sciences to expand access to scalable, research-grade and current good …
-
Pharma industry laments Trump’s tariff on branded drugs
The pharmaceutical industry has widely criticised the US administration’s decision to impose a 100% tariff on branded drugs imported into …
-
Halozyme and Vertex sign deal for Hypercon technology
Halozyme Therapeutics' subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former's …
-
Why Timelines Break Down in Rare Kidney Drug Development
Enrollment challenges continue to be a defining constraint in nephrology research. In a January 2026 snapshot of GlobalData’s clinical trial …
-
Gilead outlays $5bn to acquire ADC specialist Tubulis
Gilead will acquire antibody-drug conjugate (ADC) developer Tubulis in a deal worth up to $5bn, continuing the big pharma company’s …
-
In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe
Last year saw the largest fall in US contract manufacturing (CM) deals for FDA-approved drugs in five years. Despite the …
-
Apnimed obtains up to $150m in funds for commercial launch of AD109
Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HealthCare Royalty Partners (HCRx) …
-
The hidden bottleneck in digital healthcare: Why hospital wireless networks are under pressure in 2026
Healthcare is entering a new era of digital transformation. In the US, competition among leading providers is driving rapid adoption …
-
The evolving landscape of subcutaneous drug administration
In pharmaceutical development, several major trends are shaping the future of drug delivery. For decades now, the industry has been …
-
CGT’s next obstacle: Securing the leukapheresis supply chain
Clinical trial numbers for CAR-T therapies have risen dramatically in recent years, and as these programmes expand beyond oncology into …
